Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients with Advanced Malignancies

摘要

PurposeS-CKD602 is a pegylated liposomal formulation of CKD-602, a semi-synthetic camptothecin analogue. Pegylated (STEALTH^®) liposomes can achieve extended drug exposure in plasma and tumor. Based on promising preclinical data, the first phase I study of S-CKD602 was performed in patients (pts) with refractory solid tumors.